Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Cytarabine (Primary) ; Idarubicin (Primary) ; Decitabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 14 Feb 2017 Status changed to discontinued because there were other competing protocols.
- 10 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.